medigraphic.com
ISSN 2078-7162 (Print)

2014, Number 1

<< Back Next >>

Rev Cub de Med Fis y Rehab 2014; 6 (1)

Iontoforesis with prednisolona in the treatment of the illness of Peyronie

Rodríguez HEI, Pérez RZM, Guerrero DL, Ramírez SMR

Language: Spanish
References: 37
Page: 41-52
PDF size: 104.85 Kb.


ABSTRACT

Objective: To demonstrate the utility of the iontophoresis with prednisolone in the breakup of the fibrous badge and in the disappearance of the symptom pain of the patients with the illness of Peyronie.
Method: He/she was carried out a prospective quasi experimental, longitudinal study in 30 patients with the diagnosis (clinical and echographic) of illness of Peyronie. The results were analyzed and they processed for technical descriptive (percentages, he/she mediates, deviation standard, (minima and maxima) and explicit inferential for hypothesis tests where a significance level was used of (p ‹0,05) and the non parametric test of Wilcoxon was used with an error type I (p ‹0,05), to establish significant differences before and after the treatment.
Results: Changes were observed statistically significant so much clinical as imaging in 70 % of the patients, with decrease of more than 30 % of the fibrous badge and disappearance of the pain; that which evidenced the effectiveness of the applied treatment.
Conclusions: The iontophoresis with prednisolone to 20 was effective in the treatment of the illness of Peyronie to eliminate or to diminish in most of the patients as much the pain as the badge of the penis verified by ultrasound.


REFERENCES

  1. Lewis RW, Jordan GH. Surgery for erectile dysfunction. En Walsh P. C et al Editors. Campbell´s Urology, 8 ed. Saunders, Philadelphia. 2002. pp. 1696-1705.

  2. Jordan GH, et al. Peyronie s diseases. Campbells-Walsh Urology, 8 ed. Chapter 25. 2007.

  3. Rosen R; Catania J; Lue T; Althof S; Henne J; Hellstrom W; Levine L. Impact of Peyronie's disease on sexual and psychosocial functioning: qualitative findings in patients and controls. J Sex Med; 5(8):1977-84, 2008 Aug.

  4. Pinar R. Álvarez JA., Martelo Villar F., Chantada Aval V., Arranz López JL. Enfermedad de Peyronie. SECPRE. 2005; 3 (5).

  5. Hellstron WJ, Bivalacqua TJ. Peroynie's disease: etiology, medical and surgical J. Androl 2000 May-Jun; 21(3):347-54.

  6. Petropoulos P, Ferri s Clinical Avidsor.1 ed: Peyronie´s disease. 2008 p. 688.

  7. Fraga R. Manejo terapéutico de la enfermedad de Peyroníe. mar-ago 2004 (URNET I)

  8. Kendirci M, Trost L, Sikka SC. Diabetes mellitus is associated with severe Peyronies disease. Feb;99(2):386-6.2007.

  9. Duran Merino R. Enfermedad de Peyronie. Act Urol Españolas, dic. 2008.

  10. Vázquez J. Enfermedad de Peyronie-información urología para pacientes y profesionales. Buenos Aires. Urología. 2006

  11. Gholami SS, González Cadavid NF, Lin C-S. Rajfer J, Lue T. Peyronie´s disease: a review. J Urol, 69: 1234-41, April 2003.

  12. Rosales CS, Ramírez GP, Morales Barturen SM, Mandarino A. Avances en el tratamiento de la enfermedad de Peyronie. Rev. Post-grado VIa, Cátedra de medicina,148; 16-9, Agosto. 2005.

  13. Lemourt Oliva M. et: al. Enfermedad de Peyroníe, Evaluación de tres modalidades terapéuticas. propóleo, láser y propóleo mas láser. ARC, España Urol. 58,9 (931-35) 2006.

  14. Levine LA, Estrada CR, Shou W, Cole, A. Tunica albuginea tissue analysis after electromotive drug administration". J Urol 2003; 169:1775-78.

  15. Levine LA, Goldman KE, Greenfield J M. Experience with intraplaque injection of verapamil for Peyronie´s disease. J Urol 2004; 168:621-6.

  16. Haag SM; Hauck EW; Eickelberg O; Szardening-Kirchner C; Diemer T; Weidner W. Investigation of the antifibrotic effect of IFN-gamma on fibroblasts in a cell culture model of Peyronie's disease. Eur Urol .2008 Feb; 53(2):425-30.

  17. Jalkut M; Gonzalez-Cadavid N; Rajfer J. Peyronie's Disease: A Review. Rev Urol 2003; 5(3):142-8.

  18. Safarinejad MR; Hosseini SY; Kolahi AA. Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie's disease: a double-blind, placebo controlled, randomized study. J Urol. Oct 2007; 178(4 Pt 1):1398-403.

  19. Jordan GH. The use of intralesional clostridial collagenase injection therapy for Peyronie's disease: a prospective, single-center, non-placebo-controlled study. J Sex Med; Jan 2008; 5(1):180-7.

  20. Taylor FL; Levine LA. Non-surgical therapy of Peyronie's disease. Asian J Androl 2008 Jan; 10(1):79-87.

  21. Bennett NE; Guhring P; Mulhall JP. Intralesional verapamil prevents the progression of Peyronie disease. Urology Jun 2007; 69(6):1181-4.

  22. Incrocci L; Hop WC; Seegenschmiedt HM. Radiotherapy for Peyronie's Disease: a European survey. Acta Oncol . 2008; 47(6):1110-2.

  23. Levine LA; Newell M; Taylor FL. Penile traction therapy for treatment of Peyronie's disease: a single-center pilot study. J Sex Med;5(6):1468-73, 2008 Jun.

  24. Cabello Benavente R, Moncada Iribarren I, .De Palacio España A, Hernández Villaverde A, Monzo J I, Hernández Fernández C. Iontoforesis transdérmica con Dexametasona y Verapamilo para la enfermedad de Peyronie: Actas Urológicas Españolas 29(10) nov. 2005.

  25. Rield CR, Plas E, Engelhardt P, et al. Iontophoresis for treatment of Peyronie´s disease. J Urol; 163:95-99. 2000.

  26. Vademécum. 30. NF 25. 3003. 2007.

  27. Cuba. Ministerio de Salud Pública. Dirección Nacional de Medicamentos. Formulário Nacional de medicamentos. La Habana: Editorial Ciencias Médicas, 2006. Pp. 357-9.

  28. Martínez Morillo M, Pastor Vega J.M., Sendra Portero F. Manual de medicina física. España: Editorial Harcourt Brau,1998.

  29. Martín Cordero J.E. Agentes físicos terapéuticos. La Habana: Editorial Ciencias Médicas, 2008.

  30. Kumar MG; Lin S. Transdermal iontophoresis: impact on skin integrity as evaluated by various methods. Crit Rev Ther Drug Carrier Syst; 25(4):381-401, 2008.

  31. Molokhia SA; Zhang Y; Higuchi WI; Li SK. Iontophoretic transport across a multiple membrane system. J Pharm Sci. 2008; 97(1):490-505.

  32. Molokhia SA; Zhang Y; Higuchi WI; Li SK. Iontophoretic transport across a multiple membrane system. J Pharm Sci. 2008;97(1):490-505.

  33. Gurney B; Wascher D; Eaton L; Benesh E; Lucak J. The effect of skin thickness and time in the absorption of dexamethasone in human tendons using iontophoresis. J Orthop Sports Phys Ther 2008; 38(5):238-45.

  34. Di Stasi SM, Giannantoni A, Capelli G, Jannin EA, Virgili G, Storti L. Transdermal electromotive administration of verapamil and dexamethasone for Peyronie´s disease. BJU Int; 91:825-829. 2003

  35. Espada JD, Mansur JD, Motorota J, Cabrera A, Echevarria JC. Enfermedad de Peyronie: Experiencias con distintas modalidades de tratamiento en 20 pacientes. Com Cient Tecn 2006; 12(1): 120-3.

  36. Bergues Cabarles L., Gomez Luna L., La electroterapia: una alternativa terapéutica para el tratamiento de tumores, Rev Cubana Med 2003:42(6) Nov.-Dic.

  37. Bergues Cabarles L, Camue HC, Perez RB, Suárez CR, Hinojosa RA, Montes de Oca LG et al. Electrochemical treatmentof Mouse Erlich tumor whit direct electric current. Bioelectromagnetics 2001. 22:316-22




2020     |     www.medigraphic.com